ClinicalTrials.gg
CompletedNCT02540265Updated Jun 14, 2017Results posted

Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery

A Phase 2 interventional study of N1539 and Intravenous Placebo in Pain, Post-operative, sponsored by Baudax Bio. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-06-14.

Sponsored by Baudax Bio · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing meloxicam in Pain, Postoperative — 2 open to participants now, 3 under way, none of them phase 3. Meloxicam · Pain, Postoperative.

Enrollment
17th of 24
59 · median 112
Started
2015
with 1 other
Phase 2
10 of 24
1 open now
Registered
2nd of 24
by date
Lead sponsor
7 of 24
Baudax Bio

Among the 24 studies testing meloxicam in Pain, Postoperative, this one is the 17th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 2, and was the 2nd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 24 studies testing meloxicam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About meloxicam

Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing meloxicam in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety of N1539 in subjects with acute moderate to severe pain following unilateral bunionectomy.

03

Conditions studied

  • Pain, Post-operative

Keywords

  • Bunion
  • Bunionectomy
  • Pain
  • Analgesia
  • N1539
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily provide written .
  • Male or female between 18 and 75 years of age, inclusive.
  • Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair
  • Be American Society of Anesthesiology (ASA) physical class 1 or 2.
  • Female subject are eligible only if all the following apply:

    • Not pregnant;
    • Not lactating;
    • Not planning to become pregnant during the study;
    • Commit to the use of an acceptable form of for the duration of the study through Day 30.
  • Have a ≤35 kg/m2
  • Be able to understand the study procedures, comply with all study procedures, and agree to participate in the study program.

Exclusion criteria

Exclusion Criteria:

  • Have a known allergy to meloxicam or any of N1539, D5W, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs) or to any peri- or postoperative medications used in this study.
  • Have a abnormal clinical laboratory test value.
  • Have history of or positive test results for , or or C.
  • Have a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study.
  • Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants.
  • Have another painful physical condition that may confound the assessments of post operative pain.
  • Have a history of syncope or other syncopal attacks.
  • Have evidence of a clinically significant 12 lead abnormality.
  • Have a history of alcohol abuse (regularly drinks > 4 units of alcohol per day; 8 oz. beer, 3 oz. wine, 1 oz. spirits) or prescription/illicit drug abuse..
  • Have positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse.
  • Have been receiving or have received chronic opioid therapy defined as greater than 15 morphine equivalents units per day for greater than 3 out of 7 days per week over a one-month period within 12 months.
  • Use concurrent therapy that could interfere with the evaluation of efficacy or safety, such as any drugs which in the investigator's opinion may exert significant analgesic properties or act synergistically with N1539.
  • Unable to discontinue medications, that have not been at a stable dose for at least 14 days prior to the scheduled bunionectomy procedure, within 5 half lives of the specific prior medication (or, if half life is not known, within 48 hours) before dosing.
  • Have utilized , either systemically, inhalational either intranasally or oral, or by intra-articular injection, within 14 days prior to the study.
  • Have received any product within 30 days before dosing with study medication.
  • Be receiving warfarin, lithium, or a combination of furosemide with either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker
  • Be currently receiving treatment with oral meloxicam (Mobic®)
  • Have previously received N1539 in clinical trials, or had bunionectomy in the last 3 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    N1539 30mg

    N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.

    Drug: N1539

  • Experimental
    N1539 60mg

    N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.

    Drug: N1539

  • Placebo comparator
    IV Placebo

    IV Placebo every 24 hours for up to 3 doses.

    Drug: Intravenous Placebo

Interventions

  • DrugN1539

    Also known as: Intravenous meloxicam

  • DrugIntravenous Placebo
06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events

    Number of subjects reporting treatment emergent adverse events

    Time frame: Through Day 30 Follow-up

Secondary outcomes

  1. Effect Size of N1539 Doses Using the Summed Pain Intensity Difference Over the First 48 Hours (SPID48)

    Effect size was estimated based on SPID48 derived using 2-hour windowed last observation carried forward (W2LOCF) method and an analysis of covariance (ANCOVA) model that included treatment and baseline PI score.

    Time frame: 48 Hours

  2. Summed Pain Intensity Difference Over the First 48 Hours (SPID48)

    Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.

    Time frame: 48 Hours

  3. Summed Pain Intensity Difference (SPID) at Other Intervals

    Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.

    Time frame: 48 Hours

  4. Number of Subjects With Use of Rescue Medication (Oral Opioids)

    Time frame: 48 hours

07

Results

Posted Jun 14, 2017

Participant flow

Participant flow — Overall Study
MilestoneN1539 30mgN1539 60mgIV Placebo
Started202019
Treatment completion201918
Completed202018
Not completed001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryNumber of Subjects With Adverse Events

Number of subjects reporting treatment emergent adverse events

Time frame:
Through Day 30 Follow-up
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events
ParticipantsN1539 30mgN1539 60mgIV Placebo
Number of Subjects With Adverse Events121010
SecondaryEffect Size of N1539 Doses Using the Summed Pain Intensity Difference Over the First 48 Hours (SPID48)

Effect size was estimated based on SPID48 derived using 2-hour windowed last observation carried forward (W2LOCF) method and an analysis of covariance (ANCOVA) model that included treatment and baseline PI score.

Time frame:
48 Hours
Reported as:
Least squares mean · units on a scale
Effect Size of N1539 Doses Using the Summed Pain Intensity Difference Over the First 48 Hours (SPID48)
units on a scaleN1539 30mgN1539 60mgIV Placebo
Effect Size of N1539 Doses Using the Summed Pain Intensity Difference Over the First 48 Hours (SPID48)-9241.9 ± 1411.74-8350.6 ± 1413.30-1991.3 ± 1448.20
Statistical analysis
  • N1539 30mg vs IV Placebo · Effect size: 1.01
  • N1539 60mg vs IV Placebo · Effect size: 0.87
SecondarySummed Pain Intensity Difference Over the First 48 Hours (SPID48)

Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.

Time frame:
48 Hours
Reported as:
Least squares mean · units on a scale
Summed Pain Intensity Difference Over the First 48 Hours (SPID48)
units on a scaleN1539 30mgN1539 60mgIV Placebo
Summed Pain Intensity Difference Over the First 48 Hours (SPID48)-9241.9 ± 1411.74-8350.6 ± 1413.30-1991.3 ± 1448.20
Statistical analysis
  • N1539 30mg vs IV Placebo · t-test, 2 sided · p = 0.0049
  • N1539 60mg vs IV Placebo · t-test, 2 sided · p = 0.0076
SecondarySummed Pain Intensity Difference (SPID) at Other Intervals

Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID was better.

Time frame:
48 Hours
Reported as:
Least squares mean · units on a scale
Summed Pain Intensity Difference (SPID) at Other Intervals
units on a scaleN1539 30mgN1539 60mgIV Placebo
SPID6 (Hour 0-6)-793.87 ± 172.45-663.17 ± 172.64146.22 ± 176.91
SPID12 (Hour 0-12)-1655.1 ± 338.78-1334.9 ± 339.15319.67 ± 347.53
SPID24 (Hour 0-24)-3024.0 ± 644.63-2793.3 ± 645.34276.46 ± 661.28
SPID12-24 (Hour 12-24)-1368.9 ± 343.34-1458.4 ± 343.72-43.21 ± 352.21
SPID12-48 (Hour 12-48)-7586.8 ± 1121.12-7015.7 ± 1122.35-2311.0 ± 1150.07
SPID24-48 (Hour 24-48)-6217.9 ± 817.22-5557.3 ± 818.12-2267.8 ± 838.33
Statistical analysis
  • N1539 30mg vs IV Placebo · t-test, 2 sided · p = <0.05 (Applies to SPID 0-6, SPID 0-12, SPID 0-24, SPID 12-24, SPID 12-48, and SPID 24-48)
  • N1539 60mg vs IV Placebo · t-test, 2 sided · p = <0.05 (Applies to SPID 0-6, SPID 0-12, SPID 0-24, SPID 12-24, SPID 12-48, and SPID 24-48)
SecondaryNumber of Subjects With Use of Rescue Medication (Oral Opioids)
Time frame:
48 hours
Reported as:
Count of participants · Participants
Number of Subjects With Use of Rescue Medication (Oral Opioids)
ParticipantsN1539 30mgN1539 60mgIV Placebo
Hour 0-24201819
Hour 24-48111014
Hour 0-48201819

Adverse events

Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
N1539 30mg—0/20 (0%)12/20 (60%)
N1539 60mg—0/20 (0%)10/20 (50%)
IV Placebo—0/19 (0%)10/19 (52.6%)
Most frequent other events
Most frequent other events
EventN1539 30mgN1539 60mgIV Placebo
NauseaGastrointestinal disorders6/204/204/19
HeadacheNervous system disorders2/203/204/19
DizzinessNervous system disorders3/202/201/19
VomitingGastrointestinal disorders3/200/201/19
Decreased appetiteMetabolism and nutrition disorders0/201/202/19
PruritusSkin and subcutaneous tissue disorders1/202/200/19
ErythemaSkin and subcutaneous tissue disorders2/200/201/19
Muscle spasmsMusculoskeletal and connective tissue disorders2/200/200/19
ConstipationGastrointestinal disorders1/201/200/19
SomnolenceNervous system disorders1/201/200/19

Baseline characteristics

Analysis population includes all subjects randomized to treatment

Age, Categorical
Age, Categorical(Participants)N1539 30mgN1539 60mgIV PlaceboTotal
<=18 years0112
Between 18 and 65 years19161651
>=65 years1326
Age, Continuous
Age, Continuous(years)N1539 30mgN1539 60mgIV PlaceboTotal
Mean47.6 ± 12.6644.9 ± 16.6749.2 ± 12.8147.2 ± 14.06
Sex: Female, Male
Sex: Female, Male(Participants)N1539 30mgN1539 60mgIV PlaceboTotal
Female16181448
Male42511
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)N1539 30mgN1539 60mgIV PlaceboTotal
Hispanic or Latino3003
Not Hispanic or Latino17201956
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)N1539 30mgN1539 60mgIV PlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1091130
White1010828
More than one race0101
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)N1539 30mgN1539 60mgIV PlaceboTotal
United States20201959
Baseline Pain Intensity (0-10 NPRS)
Baseline Pain Intensity (0-10 NPRS)(units on a scale)N1539 30mgN1539 60mgIV PlaceboTotal
Mean7.7 ± 2.007.4 ± 1.907.7 ± 2.247.6 ± 2.02
08

Study locations

1 site
  • Chesapeake Research Group, LLC
    Pasadena, Maryland, United States
09

References and documents

Publications

  • Viscusi ER, Gan TJ, Bergese S, Singla N, Mack RJ, McCallum SW, Du W, Hobson S. Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. Reg Anesth Pain Med. 2019 Mar;44(3):360-368. doi: 10.1136/rapm-2018-100184. Epub 2019 Feb 7. PubMed 30737315 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2015
First posted
Sep 3, 2015
Start
Aug 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Jun 14, 2017
Last update
Jun 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02540265
Lead sponsor
Baudax Bio
Responsible party
Sponsor
First posted
Sep 3, 2015
Start date
Aug 2015
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Jun 14, 2017
Last update
Jun 14, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion